https://pubmed.ncbi.nlm.nih.gov/32251768/
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
https://www.sciencedirect.com/science/article/pii/S0166354220302011#:~:text=Ivermectin%20is%20an%20inhibitor%20of,CoV%2D2)%20in%20vitro.&text=A%20single%20treatment%20able%20to,48%20h%20in%20cell%20culture.&text=Ivermectin%20is%20FDA%2Dapproved%20for,has%20a%20potential%20for%20repurposing.